PharmaPoint: Microvascular Complications of Diabetes - Germany Drug Forecast and Market Analysis to 2022, New Report Launched

The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

The currently marketed product with the highest growth rate over the forecast period will be Regeneron/Bayer’s Eylea. Even though the drug is still in the pipeline for DME, it is being used off-label already. Its usage will drastically increase upon its approval for the DME indication in 2014; however, it might meet some reimbursement opposition in Germany and apply a more aggressive pricing strategy.

Scope

• Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in Germany from 2012-2022.
• Analysis of the impact of key events as well the drivers and restraints affecting the Germany MCD market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for MCD
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2012-2022 in Germany

Spanning over 144 pages, 38 tables and 6 figures, “PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

See  more information visit: http://www.marketresearchreports.com/globaldata/pharmapoint-microvascular-complications-diabetes-germany-drug-forecast-and-market    

 Find All Healthcare Reports at- http://www.marketresearchreports.com/healthcare     

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter